Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTMQB37)

• DTT Name: Interferon alpha/beta receptor 2 (IFNAR2) DTT Info
• Gene Name: IFNAR2

Molecule-Related Drug & Molecule List

6 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anifrolumab	DM3FPAQ	Systemic lupus erythematosus	4A40.0	Approved	[1]
Interferon Alfa-2b, Recombinant	DM3TPY8	Hairy cell leukaemia	2A82.2	Approved	[2]
Interferon alfa-n1	DM4AK0Q	Chronic myelogenous leukaemia	2A20.0	Approved	[3]
Interferon alfacon-1	DM90WJH	Hepatitis C	1E51	Approved	[4]
Interferon beta-1b	DMCN61Z	Multiple sclerosis	8A40	Approved	[5]
Sifalimumab	DM1BS03	Renal cell carcinoma	2C90	Approved	[6]

1 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alfa-interferon	DMXMK5S	Endometriosis	GA10	Phase 1	[7]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoie... Leuk Res. 2009 Aug;33(8):e111-3.
• [3] Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 1998 Apr;27(4):1121-7.
• [4] Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009 Jun;49(6):1838-46.
• [5] Interferon-beta(1b) Treatment in Neuromyelitis Optica. Eur Neurol. 2009 Jul 7;62(3):167-170.
• [6] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [7] New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.